Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable HER2-Low Breast Carcinoma”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Early research (Phase 1)Ended earlyNCT02751528
What this trial is testing

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Who this might be right for
Cancer
NantBioScience, Inc. 3
Testing effectiveness (Phase 2)Study completedNCT06188559
What this trial is testing

BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 56
Large-scale testing (Phase 3)Active Not RecruitingNCT03734029
What this trial is testing

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Who this might be right for
Breast Cancer
Daiichi Sankyo 557
Testing effectiveness (Phase 2)UnknownNCT05018676
What this trial is testing

ARX788 in Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer With Low Expression of HER2
Fudan University 54
Large-scale testing (Phase 3)Looking for participantsNCT06079983
What this trial is testing

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Who this might be right for
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 400
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableStudy completedNCT06188494
What this trial is testing

UNFOLD Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 405
Not applicableStudy completedNCT06125314
What this trial is testing

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Who this might be right for
Breast NeoplasmsBreast CancerBreast Carcinoma+2 more
AstraZeneca 517
Not applicableLooking for participantsNCT06210776
What this trial is testing

Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Who this might be right for
HER2-positive Breast CancerHER2-low Breast CancerBreast Cancer+1 more
Daiichi Sankyo 800
Not applicableStudy completedNCT04807595
What this trial is testing

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Who this might be right for
Breast Cancer
AstraZeneca 798
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Testing effectiveness (Phase 2)Study completedNCT05340413
What this trial is testing

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

Who this might be right for
HER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer
SOLTI Breast Cancer Research Group 65
Testing effectiveness (Phase 2)UnknownNCT05845138
What this trial is testing

SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Who this might be right for
Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 116
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150208
What this trial is testing

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

Who this might be right for
Breast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer
Fudan University 140
Not applicableEnded earlyNCT05592483
What this trial is testing

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 78
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06547476
What this trial is testing

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Who this might be right for
Breast Cancer
Guangdong Provincial People's Hospital 40
Testing effectiveness (Phase 2)Study completedNCT02614794
What this trial is testing

Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen Inc. 612
Not applicableLooking for participantsNCT06727227
What this trial is testing

Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 135
Load More Results